Boostimmune

Executive Summary

Boostimmune is a preclinical-stage biotechnology company developing immunotherapies aimed at enhancing the body's natural immune response against cancer and infectious diseases. Based in San Diego, the company leverages its proprietary platform to design therapies that boost immune system activity, potentially addressing unmet needs in oncology and infectious disease. While still in early development, Boostimmune's approach has broad applicability and could lead to novel treatment options. The company's preclinical stage suggests that significant milestones, including IND-enabling studies and potential partnership discussions, are likely within the next 12-24 months. However, given the lack of publicly available pipeline data, the risk profile remains high, typical for early-stage biotech ventures.

Upcoming Catalysts (preview)

• Q2 2026Preclinical Data Release for Lead Candidate50% success
• Q4 2026IND Filing for Lead Program30% success
• H2 2026Partnership or Licensing Deal25% success